Raras
Buscar doenças, sintomas, genes...
Atrofia muscular bulbo-espinhal
ORPHA:206701PCDT · SUSDOENÇA RARA

O trato corticoespinhal ou trato piramidal é uma grande coleção de axônios que viajam entre o córtex cerebral do cérebro e a medula espinhal.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Doença neurodegenerativa rara que afeta neurônios motores, causando fraqueza muscular progressiva, espasticidade e, em alguns casos, convulsões e anomalias cerebelares. Pode apresentar atraso motor, luxação do quadril e outras malformações.

Pesquisas ativas
9 ensaios
25 total registrados no ClinicalTrials.gov
Publicações científicas
58 artigos
Último publicado: 2025
🏥
SUS: Cobertura mínimaScore: 35%
PCDT disponívelTriagem neonatal (Fase 5)
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🧠
Neurológico
45 sintomas
💪
Músculos
11 sintomas
👁️
Olhos
7 sintomas
📏
Crescimento
6 sintomas
🫁
Pulmão
3 sintomas
😀
Face
3 sintomas

+ 46 sintomas em outras categorias

Características mais comuns

Aplasia/Hipoplasia do cerebelo
Convulsão
Atraso motor
Dilatação dos ventrículos laterais
Espasticidade
Rabdomiólise induzida por infecção viral
131sintomas
Sem dados (131)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 131 características clínicas mais associadas, ordenadas por frequência.

Aplasia/Hipoplasia do cerebeloAplasia/Hypoplasia of the cerebellum
ConvulsãoSeizure
Atraso motorMotor delay
Dilatação dos ventrículos lateraisDilation of lateral ventricles
EspasticidadeSpasticity

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2025
Total histórico58PubMed
Últimos 10 anos11publicações
Pico20153 papers
Linha do tempo
2025Hoje · 2026🧪 1992Primeiro ensaio clínico📈 2015Ano de pico
Publicações por ano (últimos 10 anos)

Triagem neonatal (Teste do Pezinho)

👶
Teste: qPCR para deleção de SMN1 em sangue seco
Fase 5 do PNTNpending
Incidência no Brasil: 1:10.000

A triagem neonatal permite diagnóstico precoce e início imediato do tratamento.

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

11 genes identificados com associação a esta condição.

AGTPBP1Cytosolic carboxypeptidase 1Candidate gene tested inRestrito
FUNÇÃO

Metallocarboxypeptidase that mediates protein deglutamylation of tubulin and non-tubulin target proteins (PubMed:22170066, PubMed:24022482, PubMed:30420557). Catalyzes the removal of polyglutamate side chains present on the gamma-carboxyl group of glutamate residues within the C-terminal tail of alpha- and beta-tubulin (PubMed:22170066, PubMed:24022482, PubMed:30420557). Specifically cleaves tubulin long-side-chains, while it is not able to remove the branching point glutamate (PubMed:24022482).

LOCALIZAÇÃO

CytoplasmCytoplasm, cytosolNucleusMitochondrion

VIAS BIOLÓGICAS (1)
Carboxyterminal post-translational modifications of tubulin
MECANISMO DE DOENÇA

Neurodegeneration, childhood-onset, with cerebellar atrophy

An autosomal recessive disorder characterized by early onset of progressive neurodegeneration affecting the central and peripheral nervous systems. Clinical features include global developmental delay, impaired intellectual development, poor or absent speech, and motor abnormalities. Brain imaging shows cerebellar atrophy. Death in childhood may occur.

INTERAÇÕES PROTEICAS (1)
OUTRAS DOENÇAS (2)
neurodegeneration, childhood-onset, with cerebellar atrophypontocerebellar hypoplasia type 1
HGNC:17258UniProt:Q9UPW5
EXOSC3Exosome complex component RRP40Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Non-catalytic component of the RNA exosome complex which has 3'->5' exoribonuclease activity and participates in a multitude of cellular RNA processing and degradation events. In the nucleus, the RNA exosome complex is involved in proper maturation of stable RNA species such as rRNA, snRNA and snoRNA, in the elimination of RNA processing by-products and non-coding 'pervasive' transcripts, such as antisense RNA species and promoter-upstream transcripts (PROMPTs), and of mRNAs with processing defe

LOCALIZAÇÃO

CytoplasmNucleus, nucleolusNucleus

VIAS BIOLÓGICAS (5)
mRNA decay by 3' to 5' exoribonucleaseATF4 activates genes in response to endoplasmic reticulum stressKSRP (KHSRP) binds and destabilizes mRNAButyrate Response Factor 1 (BRF1) binds and destabilizes mRNATristetraprolin (TTP, ZFP36) binds and destabilizes mRNA
MECANISMO DE DOENÇA

Pontocerebellar hypoplasia 1B

A severe autosomal recessive neurologic disorder characterized by a combination of cerebellar and spinal motor neuron degeneration beginning at birth. There is diffuse muscle weakness, progressive microcephaly, global developmental delay, and brainstem involvement.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
30.1 TPM
Testículo
28.1 TPM
Fibroblastos
21.2 TPM
Cervix Endocervix
16.4 TPM
Ovário
15.4 TPM
OUTRAS DOENÇAS (2)
pontocerebellar hypoplasia type 1Bpontocerebellar hypoplasia type 1
HGNC:17944UniProt:Q9NQT5
TSEN2tRNA-splicing endonuclease subunit Sen2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Constitutes one of the two catalytic subunit of the tRNA-splicing endonuclease complex, a complex responsible for identification and cleavage of the splice sites in pre-tRNA. It cleaves pre-tRNA at the 5'- and 3'-splice sites to release the intron. The products are an intron and two tRNA half-molecules bearing 2',3'-cyclic phosphate and 5'-OH termini. There are no conserved sequences at the splice sites, but the intron is invariably located at the same site in the gene, placing the splice sites

LOCALIZAÇÃO

NucleusNucleus, nucleolus

VIAS BIOLÓGICAS (1)
tRNA processing in the nucleus
MECANISMO DE DOENÇA

Pontocerebellar hypoplasia 2B

A disorder characterized by an abnormally small cerebellum and brainstem, and progressive microcephaly from birth combined with extrapyramidal dyskinesia. Severe chorea occurs and epilepsy is frequent. There are no signs of spinal cord anterior horn cells degeneration.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
11.4 TPM
Ovário
11.0 TPM
Cérebro - Hemisfério cerebelar
10.4 TPM
Útero
10.0 TPM
Fibroblastos
9.8 TPM
OUTRAS DOENÇAS (2)
pontocerebellar hypoplasia type 2Bpontocerebellar hypoplasia type 2
HGNC:28422UniProt:Q8NCE0
TSEN54tRNA-splicing endonuclease subunit Sen54Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Non-catalytic subunit of the tRNA-splicing endonuclease complex, a complex responsible for identification and cleavage of the splice sites in pre-tRNA. It cleaves pre-tRNA at the 5' and 3' splice sites to release the intron. The products are an intron and two tRNA half-molecules bearing 2',3' cyclic phosphate and 5'-OH termini. There are no conserved sequences at the splice sites, but the intron is invariably located at the same site in the gene, placing the splice sites an invariant distance fr

LOCALIZAÇÃO

NucleusNucleus, nucleolus

VIAS BIOLÓGICAS (1)
tRNA processing in the nucleus
MECANISMO DE DOENÇA

Pontocerebellar hypoplasia 4

A disorder characterized by an abnormally small cerebellum and brainstem, severe neonatal encephalopathy, microcephaly, myoclonus and muscular hypertonia. There is a severe inferior olivary and pontine neuronal loss and a diffuse white matter gliosis.

EXPRESSÃO TECIDUAL(Ubíquo)
Cerebelo
61.6 TPM
Cérebro - Hemisfério cerebelar
59.4 TPM
Baço
34.8 TPM
Tireoide
34.5 TPM
Próstata
33.2 TPM
OUTRAS DOENÇAS (4)
pontocerebellar hypoplasia type 4pontocerebellar hypoplasia type 2Apontocerebellar hypoplasia type 5pontocerebellar hypoplasia type 2
HGNC:27561UniProt:Q7Z6J9
EXOSC8Exosome complex component RRP43Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Non-catalytic component of the RNA exosome complex which has 3'->5' exoribonuclease activity and participates in a multitude of cellular RNA processing and degradation events. In the nucleus, the RNA exosome complex is involved in proper maturation of stable RNA species such as rRNA, snRNA and snoRNA, in the elimination of RNA processing by-products and non-coding 'pervasive' transcripts, such as antisense RNA species and promoter-upstream transcripts (PROMPTs), and of mRNAs with processing defe

LOCALIZAÇÃO

CytoplasmNucleusNucleus, nucleolus

VIAS BIOLÓGICAS (5)
mRNA decay by 3' to 5' exoribonucleaseATF4 activates genes in response to endoplasmic reticulum stressKSRP (KHSRP) binds and destabilizes mRNAButyrate Response Factor 1 (BRF1) binds and destabilizes mRNATristetraprolin (TTP, ZFP36) binds and destabilizes mRNA
MECANISMO DE DOENÇA

Pontocerebellar hypoplasia 1C

A severe autosomal recessive neurodegenerative disease characterized by cerebellar and corpus callosum hypoplasia, abnormal myelination of the central nervous system, and spinal motor neuron disease. Affected individuals manifest failure to thrive, severe muscle weakness, spasticity and psychomotor retardation. Vision and hearing are impaired.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
60.2 TPM
Testículo
43.8 TPM
Ovário
40.4 TPM
Cervix Endocervix
38.1 TPM
Fallopian Tube
37.8 TPM
OUTRAS DOENÇAS (2)
pontocerebellar hypoplasia, type 1Cpontocerebellar hypoplasia type 1
HGNC:17035UniProt:Q96B26
EXOSC9Exosome complex component RRP45Candidate gene tested inTolerante
FUNÇÃO

Non-catalytic component of the RNA exosome complex which has 3'->5' exoribonuclease activity and participates in a multitude of cellular RNA processing and degradation events. In the nucleus, the RNA exosome complex is involved in proper maturation of stable RNA species such as rRNA, snRNA and snoRNA, in the elimination of RNA processing by-products and non-coding 'pervasive' transcripts, such as antisense RNA species and promoter-upstream transcripts (PROMPTs), and of mRNAs with processing defe

LOCALIZAÇÃO

CytoplasmNucleusNucleus, nucleolusNucleus, nucleoplasm

VIAS BIOLÓGICAS (5)
mRNA decay by 3' to 5' exoribonucleaseATF4 activates genes in response to endoplasmic reticulum stressKSRP (KHSRP) binds and destabilizes mRNAButyrate Response Factor 1 (BRF1) binds and destabilizes mRNATristetraprolin (TTP, ZFP36) binds and destabilizes mRNA
MECANISMO DE DOENÇA

Pontocerebellar hypoplasia 1D

An autosomal recessive neurologic disorder with onset at birth or in infancy, and characterized by progressive axonal motor neuronopathy, severe generalized hypotonia, respiratory insufficiency, and cerebellar atrophy. Death in childhood may occur.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
43.9 TPM
Testículo
34.6 TPM
Fibroblastos
34.4 TPM
Nervo tibial
24.9 TPM
Cérebro - Hemisfério cerebelar
23.4 TPM
OUTRAS DOENÇAS (2)
pontocerebellar hypoplasia, type 1Dpontocerebellar hypoplasia type 1
HGNC:9137UniProt:Q06265
VRK1Serine/threonine-protein kinase VRK1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Serine/threonine kinase involved in the regulation of key cellular processes including the cell cycle, nuclear condensation, transcription regulation, and DNA damage response (PubMed:14645249, PubMed:18617507, PubMed:19103756, PubMed:33076429). Controls chromatin organization and remodeling by mediating phosphorylation of histone H3 on 'Thr-4' and histone H2AX (H2aXT4ph) (PubMed:31527692, PubMed:37179361). It also phosphorylates KAT5 in response to DNA damage, promoting KAT5 association with chr

LOCALIZAÇÃO

NucleusCytoplasmNucleus, Cajal body

VIAS BIOLÓGICAS (1)
Initiation of Nuclear Envelope (NE) Reformation
MECANISMO DE DOENÇA

Pontocerebellar hypoplasia 1A

A form of pontocerebellar hypoplasia, a disorder characterized by structural defects of the pons and cerebellum, evident upon brain imaging. PCH1A is an autosomal recessive form characterized by an abnormally small cerebellum and brainstem, central and peripheral motor dysfunction from birth, gliosis and spinal cord anterior horn cells degeneration resembling infantile spinal muscular atrophy. Additional features include muscle hypotonia, congenital contractures and respiratory insufficiency that is evident at birth.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
60.6 TPM
Testículo
41.3 TPM
Baço
13.9 TPM
Fibroblastos
12.9 TPM
Fallopian Tube
9.9 TPM
OUTRAS DOENÇAS (4)
neuronopathy, distal hereditary motor, autosomal recessive 10pontocerebellar hypoplasia type 1Apontocerebellar hypoplasia type 1microcephaly-complex motor and sensory axonal neuropathy syndrome
HGNC:12718UniProt:Q99986
TSEN15tRNA-splicing endonuclease subunit Sen15Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Non-catalytic subunit of the tRNA-splicing endonuclease complex, a complex responsible for identification and cleavage of the splice sites in pre-tRNA. It cleaves pre-tRNA at the 5' and 3' splice sites to release the intron. The products are an intron and two tRNA half-molecules bearing 2',3' cyclic phosphate and 5'-OH termini (PubMed:15109492, PubMed:27392077). There are no conserved sequences at the splice sites, but the intron is invariably located at the same site in the gene, placing the sp

LOCALIZAÇÃO

NucleusNucleus, nucleolus

VIAS BIOLÓGICAS (1)
tRNA processing in the nucleus
MECANISMO DE DOENÇA

Pontocerebellar hypoplasia 2F

A neurodevelopmental disorder characterized by progressive microcephaly, cognitive and motor delay, poor or absent speech, seizures, and spasticity. PCH2F inheritance is autosomal recessive.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
51.4 TPM
Brain Spinal cord cervical c-1
42.9 TPM
Linfócitos
39.4 TPM
Cólon sigmoide
33.2 TPM
Útero
32.2 TPM
OUTRAS DOENÇAS (2)
pontocerebellar hypoplasia, type 2Fpontocerebellar hypoplasia type 2
HGNC:16791UniProt:Q8WW01
SLC25A46Mitochondrial outer membrane protein SLC25A46Candidate gene tested inTolerante
FUNÇÃO

Transmembrane protein of the mitochondrial outer membrane that controls mitochondrial organization (PubMed:26168012, PubMed:27390132, PubMed:27543974). May regulate the assembly of the MICOS (mitochondrial contact site and cristae organizing system) complex which is essential to the biogenesis and dynamics of mitochondrial cristae, the inwards folds of the inner mitochondrial membrane (PubMed:27390132). Through its interaction with the EMC (endoplasmic reticulum membrane protein complex), could

LOCALIZAÇÃO

Mitochondrion outer membrane

MECANISMO DE DOENÇA

Neuropathy, hereditary motor and sensory, 6B, with optic atrophy

An autosomal recessive neurologic disorder characterized by early-onset optic atrophy, progressive visual loss, and peripheral sensorimotor neuropathy manifesting as axonal Charcot-Marie-Tooth disease, with variable age at onset and severity. Charcot-Marie-Tooth disease is a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. It is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies and primary peripheral axonal neuropathies. Peripheral axonal neuropathies are characterized by signs of axonal regeneration in the absence of obvious myelin alterations, and normal or slightly reduced nerve conduction velocities.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
35.0 TPM
Cérebro - Hemisfério cerebelar
31.7 TPM
Fibroblastos
27.1 TPM
Cerebelo
25.2 TPM
Nervo tibial
21.7 TPM
INTERAÇÕES PROTEICAS (3)
OUTRAS DOENÇAS (4)
neuropathy, hereditary motor and sensory, type 6Bpontocerebellar hypoplasia, type 1Epontocerebellar hypoplasia type 1hereditary motor and sensory neuropathy type 6
HGNC:25198UniProt:Q96AG3
SEPSECSO-phosphoseryl-tRNA(Sec) selenium transferaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Converts O-phosphoseryl-tRNA(Sec) to selenocysteinyl-tRNA(Sec) required for selenoprotein biosynthesis

LOCALIZAÇÃO

Cytoplasm

VIAS BIOLÓGICAS (1)
Selenocysteine synthesis
MECANISMO DE DOENÇA

Pontocerebellar hypoplasia 2D

A disorder characterized by postnatal onset of progressive atrophy of the cerebrum and cerebellum, microcephaly, profound intellectual disability, spasticity, and variable seizures.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Fígado
12.7 TPM
Intestino delgado
12.4 TPM
Nervo tibial
11.5 TPM
Ovário
10.7 TPM
Tireoide
10.6 TPM
OUTRAS DOENÇAS (3)
pontocerebellar hypoplasia type 2Dpontocerebellar hypoplasia type 2obsolete progressive cerebello-cerebral atrophy
HGNC:30605UniProt:Q9HD40
TSEN34tRNA-splicing endonuclease subunit Sen34Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Constitutes one of the two catalytic subunit of the tRNA-splicing endonuclease complex, a complex responsible for identification and cleavage of the splice sites in pre-tRNA. It cleaves pre-tRNA at the 5'- and 3'-splice sites to release the intron. The products are an intron and two tRNA half-molecules bearing 2',3'-cyclic phosphate and 5'-OH termini. There are no conserved sequences at the splice sites, but the intron is invariably located at the same site in the gene, placing the splice sites

LOCALIZAÇÃO

NucleusNucleus, nucleolus

VIAS BIOLÓGICAS (1)
tRNA processing in the nucleus
MECANISMO DE DOENÇA

Pontocerebellar hypoplasia 2C

A disorder characterized by an abnormally small cerebellum and brainstem, and progressive microcephaly from birth combined with extrapyramidal dyskinesia. Severe chorea occurs and epilepsy is frequent. There are no signs of spinal cord anterior horn cells degeneration.

EXPRESSÃO TECIDUAL(Ubíquo)
Sangue
71.4 TPM
Testículo
51.0 TPM
Ovário
47.6 TPM
Glândula adrenal
45.8 TPM
Cervix Endocervix
42.9 TPM
OUTRAS DOENÇAS (2)
pontocerebellar hypoplasia type 2Cpontocerebellar hypoplasia type 2
HGNC:15506UniProt:Q9BSV6

Variantes genéticas (ClinVar)

273 variantes patogênicas registradas no ClinVar.

🧬 AGTPBP1: NM_001330701.2(AGTPBP1):c.1337T>C (p.Phe446Ser) ()
🧬 AGTPBP1: NM_001286715.1(AGTPBP1):c.5G>C (p.Arg2Pro) ()
🧬 AGTPBP1: NM_001330701.2(AGTPBP1):c.3349C>T (p.Gln1117Ter) ()
🧬 AGTPBP1: NM_001330701.2(AGTPBP1):c.3407G>A (p.Arg1136His) ()
🧬 AGTPBP1: NM_001330701.2(AGTPBP1):c.3616dup (p.Tyr1206fs) ()
Ver todas no ClinVar

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
Aprovado2
3Fase 34
2Fase 26
·Pré-clínico8
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 20 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Atrofia muscular bulbo-espinhal

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

8 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

25 ensaios clínicos encontrados, 9 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
11 papers (10 anos)
#1

Analyzing real-world adverse events of spironolactone with the FAERS database.

PloS one2025

Spironolactone, a potassium-sparing diuretic, is commonly prescribed for conditions such as heart failure, hypertension, and hyperaldosteronism. This study aims to explore and analyze the safety profile of spironolactone by examining adverse event reports from the FDA Adverse Event Reporting System (FAERS) database. This study conducted a retrospective pharmacovigilance analysis using FAERS data (2004 Q1-2024 Q3). Adverse drug events (ADEs) related to spironolactone were identified and categorized by system organ class and specific adverse events. Statistical methods such as Proportional Reporting Ratio (PRR), Reporting Odds Ratio (ROR), Bayesian Confidence Propagation Neural Network (BCPNN), and Empirical Bayesian Geometric Mean (EBGM) were employed to detect potential safety signals. A total of 8,566 ADE reports were associated with spironolactone, with 2409 preferred terms and 25 system organ classes showing significant disproportionality. Notable rare ADEs identified included endometriosis male (n = 7; ROR 13615.84), 5-alpha-reductase deficiency (n = 5; ROR 1620.81), bulbospinal muscular atrophy congenital (n = 6; ROR 402.42) and double-hit lymphoma (n = 5; ROR 243.12). While most findings were consistent with spironolactone's known effects, new signals, including a potential link to male endometriosis in high-risk groups, were identified. Further research is needed to confirm these findings and improve long-term safety assessment and clinical management.

#2

Comprehensive evaluation of leuprorelin-associated adverse events: insights from FDA adverse event reporting system.

Expert opinion on drug safety2025 Mar

Leuprorelin, a gonadotropin-releasing hormone agonist, is widely used to treat hormone-related disorders. This study aims to explore and analyze the safety profile of leuprorelin by examining adverse event reports from the FDA Adverse Event Reporting System (FAERS) database. This study conducted a retrospective pharmacovigilance analysis using FAERS data from Q1 2004 to Q1 2024. Adverse drug events (ADEs) related to leuprorelin were identified and categorized by system organ class and specific adverse events. Statistical methods such as Proportional Reporting Ratio (PRR), Reporting Odds Ratio (ROR), Bayesian Confidence Propagation Neural Network (BCPNN), and Empirical Bayesian Geometric Mean (EBGM) were used to detect safety signals. A total of 63,928 ADE reports implicated leuprorelin, with 500 preferred terms and 25 system organ classes showing significant disproportionality. Notable rare ADEs identified were bulbospinal muscular atrophy congenital (n = 26; ROR 1282.72, PRR 1282.52, IC 7.91, EBGM 241.28), follicular cystitis (n = 3; ROR 126.84, PRR 126.84, IC 6.48, EBGM 89.09), and anaplastic meningioma (n = 3; ROR 46.73, PRR 46.73, IC 5.34, EBGM 40.5). Most findings were expected, but new signals like follicular cystitis, previously unreported, emerged. Further studies are essential to validate these findings, crucial for clinical monitoring and risk identification of leuprorelin.

#3

Novel insights into post-marketing AEs associated with leuprorelin: A comprehensive analysis utilizing the FAERS database.

Heliyon2024 Aug 15

This research focused on meticulously tracking and identifying adverse reactions associated with leuprorelin, a drug prescribed for conditions such as prostate cancer, endometriosis, uterine fibroids, and early-onset puberty. The main objective was to enhance patient safety and offer informed guidance on the appropriate use of this treatment. From the first quarter of 2004 to the fourth quarter of 2023, a comprehensive analysis was conducted on a significant number of adverse event reports (AERs) from the FDA Adverse Event Reporting System (FAERS) database. Data mining with dismutation analysis was conducted to quantify signals associated with adverse events (AEs) related to leuprorelin, utilizing powerful algorithms such as ROR, PRR, BCPNN, and EBGM. A total of 102 positive reaction terms (PT) spanning 24 System Organ Classes (SOCs) were identified from an analysis of 60,709 reports associated with leuprorelin use. Notably, several previously unrecognized adverse reactions were uncovered, including Artificial Menopause, Ovarian Adhesion, Follicular Cystitis, Intercepted product preparation error, among others. These findings underscore the importance of exercising additional vigilance regarding the potential adverse effects of leuprorelin, such as Abscess Sterile, Injection site granuloma, Intercepted medication error, and Bulbospinal muscular atrophy congenital. This research has successfully uncovered new and unforeseen signals associated with adverse drug reactions (ADRs) following leuprorelin administration. The study provides valuable insights into the intricate connection between ADRs and leuprorelin usage. The results underscore the crucial significance of continuous surveillance and meticulous monitoring to promptly identify and manage AEs, ultimately enhancing patient safety and well-being while undergoing leuprorelin therapy.

#4

Bulbospinal muscular atrophy (Kennedy disease) responsive to immunoglobulins?

Clinical case reports2020 Jul

A 61 year old man with facial diplegia, quadruparesis, tongue atrophy/fasciculations, bulbar speech, muscle weakness/wasting, hypotonia, tremor, dysdiadochokinesia, absent tendon reflexes, fasciculations, and gynecomastia, received immunoglobulins for suspected immune-neuropathy with limited benefit. After reconsideration, Kennedy disease was diagnosed upon 44 CAG repeats in AR. In conclusion, immunoglobulins exhibit limited benefit on immune-neuropathy in patients with coexisting KD.

#5

Central nervous system abnormalities in spinal and bulbar muscular atrophy (Kennedy's disease).

Clinical neurology and neurosurgery2019 Sep

Spinal and bulbar (bulbospinal) muscular atrophy (BSMA, SBMA, Kennedy's disease) is a progressive motor neuron disease with rare involvement of structures other than the lower motor neuron, such as the endocrine system and the central nervous system (CNS). Aim of the review was to study type and frequency of clinical, imaging, and functional (CNS) abnormalities in SBMA patients. The most frequent clinical CNS manifestations in SBMA are postural or kinetic tremor predominantly of the hands and mild cognitive impairment. The most frequent instrumental CNS abnormality in SBMA patients are white matter lesions, visible on voxel-based morphometry, magnetic resonance spectroscopy, or diffusion tensor imaging. Single patients with enlarged pituitary volume, or diminished somato-sensory representation in the cortex have been also reported. Seizures, epilepsy, ataxia, spasticity, dystonia, or migraine have not been found in SBMA patients. Only supportive treatment is available for CNS manifestations in SBMA. It is concluded that the most frequent CNS abnormalities in SBMA are tremor, cognitive impairment, and white matter lesions on new imaging modalities. CNS involvement in SBMA should not be neglected as a phenotypic manifestation of SBMA and, apart from cognitive involvement, may help to differentiate clinically SBMA from other types of motor neuron disease.

Publicações recentes

Ver todas no PubMed

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Atrofia muscular bulbo-espinhal.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Atrofia muscular bulbo-espinhal

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Analyzing real-world adverse events of spironolactone with the FAERS database.
    PloS one· 2025· PMID 40961031mais citado
  2. Comprehensive evaluation of leuprorelin-associated adverse events: insights from FDA adverse event reporting system.
    Expert opinion on drug safety· 2025· PMID 39469972mais citado
  3. Novel insights into post-marketing AEs associated with leuprorelin: A comprehensive analysis utilizing the FAERS database.
    Heliyon· 2024· PMID 39157412mais citado
  4. Bulbospinal muscular atrophy (Kennedy disease) responsive to immunoglobulins?
    Clinical case reports· 2020· PMID 32695362mais citado
  5. Central nervous system abnormalities in spinal and bulbar muscular atrophy (Kennedy's disease).
    Clinical neurology and neurosurgery· 2019· PMID 31351215mais citado

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:206701(Orphanet)
  2. MONDO:0016113(MONDO)
  3. Atrofia Muscular Espinhal — AME(PCDT · Ministério da Saúde)
  4. GARD:20365(GARD (NIH))
  5. Variantes catalogadas(ClinVar)
  6. Busca completa no PubMed(PubMed)
  7. Q56013794(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Atrofia muscular bulbo-espinhal
Compêndio · Raras BR

Atrofia muscular bulbo-espinhal

ORPHA:206701 · MONDO:0016113
🇧🇷 Brasil SUS
Triagem
qPCR para deleção de SMN1 em sangue seco
PNTN
Fase 5
Incidência BR
1:10.000
Geral
Ensaios
9 ativos
MedGen
UMLS
C0393547
EuropePMC
Wikidata
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades